Biotech Stock Nanobiotix (NBTX) Is Up 660% This Year -- Here's Why the Rally Could Continue

Group 1 - Nanobiotix is a French biotechnology company that has experienced a significant stock price increase of 660% in 2025 as of November 18, attracting investor interest [1] - The company focuses on the discovery, development, manufacture, and commercialization of physics-based nanotherapeutics aimed at improving health outcomes for cancer patients and others with challenging diseases [2] - Nanobiotix has secured financing from major players like Johnson & Johnson, indicating confidence in its potential [4] Group 2 - The company generated negligible revenue until 2023, when it reported $30 million, with a current run rate slightly below that figure [5] - Nanobiotix has a market capitalization of $1 billion, categorizing it as a small-cap stock, which tends to be more volatile [5] - The company recently secured up to $71 million through a royalty-based agreement with Healthcare Royalty Partners, which is non-dilutive to existing shareholders [5]